Aldose reductase inhibition suppresses airway inflammation

Umesh C S Yadav, Kota Ramana, Satish Srivastava

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Airway inflammation induced by reactive oxygen species (ROS)-mediated activation of redox-sensitive transcription factors is the hallmark of asthma, a prevalent chronic respiratory disease. In various cellular and animal models, we have recently demonstrated that, in response to multiple stimuli, aldose reductase (AKR1B1) regulates the inflammatory signals via NF-kappa B activation. Since NF-κB activation is implicated in asthma pathogenesis, we investigated whether AKR1B1 inhibition could prevent ovalbumin (Ova)- and ragweed pollen extract (RWE)-induced airway inflammation and hyper-responsiveness in mice models and tumor necrosis factor-alpha (TNF-α)-, lipopolysachharide (LPS)- and RWE-induced cytotoxic and inflammatory signals in primary human small airway epithelial cells (SAEC). Sensitization and challenge with Ova or RWE caused airway inflammation and production of inflammatory cytokines, accumulation of eosinophils in airways and sub-epithelial regions, mucin production in the bronchoalveolar lavage fluid, airway hyperresponsiveness, elevated IgE levels and release of Th2 cytokines in the airway and treatment with AKR1B1 inhibitors markedly reduced these pathological changes in mice. In SAEC, treatment with TNF-α, LPS or RWE induced apoptosis, reactive oxygen species generation, synthesis of inflammatory markers IL-6, IL-8, and PGE2 and activation of NF-κB and AP-1. Pharmacological inhibition prevented these changes suggesting that AKR1B1 mediates ROS induced inflammation in small airway epithelial cells. Our results indicate that AKR1B1 inhibitors may offer a novel therapeutic approach to treat inflammatory airway diseases such as asthma.

Original languageEnglish (US)
Pages (from-to)339-345
Number of pages7
JournalChemico-Biological Interactions
Volume191
Issue number1-3
DOIs
StatePublished - May 30 2011

Fingerprint

Aldehyde Reductase
Inflammation
Reactive Oxygen Species
Asthma
Epithelial Cells
Ovalbumin
Respiratory Hypersensitivity
Tumor Necrosis Factor-alpha
Cytokines
Chemical activation
NF-kappa B
Transcription Factor AP-1
Bronchoalveolar Lavage Fluid
Mucins
Interleukin-8
Dinoprostone
Eosinophils
Immunoglobulin E
Oxidation-Reduction
Interleukin-6

Keywords

  • Airway inflammation
  • Aldose reductase
  • Asthma
  • Ragweed pollen extract
  • ROS

ASJC Scopus subject areas

  • Toxicology

Cite this

Aldose reductase inhibition suppresses airway inflammation. / Yadav, Umesh C S; Ramana, Kota; Srivastava, Satish.

In: Chemico-Biological Interactions, Vol. 191, No. 1-3, 30.05.2011, p. 339-345.

Research output: Contribution to journalArticle

Yadav, Umesh C S ; Ramana, Kota ; Srivastava, Satish. / Aldose reductase inhibition suppresses airway inflammation. In: Chemico-Biological Interactions. 2011 ; Vol. 191, No. 1-3. pp. 339-345.
@article{36e6eee978f740fbad8af1d744c67ad3,
title = "Aldose reductase inhibition suppresses airway inflammation",
abstract = "Airway inflammation induced by reactive oxygen species (ROS)-mediated activation of redox-sensitive transcription factors is the hallmark of asthma, a prevalent chronic respiratory disease. In various cellular and animal models, we have recently demonstrated that, in response to multiple stimuli, aldose reductase (AKR1B1) regulates the inflammatory signals via NF-kappa B activation. Since NF-κB activation is implicated in asthma pathogenesis, we investigated whether AKR1B1 inhibition could prevent ovalbumin (Ova)- and ragweed pollen extract (RWE)-induced airway inflammation and hyper-responsiveness in mice models and tumor necrosis factor-alpha (TNF-α)-, lipopolysachharide (LPS)- and RWE-induced cytotoxic and inflammatory signals in primary human small airway epithelial cells (SAEC). Sensitization and challenge with Ova or RWE caused airway inflammation and production of inflammatory cytokines, accumulation of eosinophils in airways and sub-epithelial regions, mucin production in the bronchoalveolar lavage fluid, airway hyperresponsiveness, elevated IgE levels and release of Th2 cytokines in the airway and treatment with AKR1B1 inhibitors markedly reduced these pathological changes in mice. In SAEC, treatment with TNF-α, LPS or RWE induced apoptosis, reactive oxygen species generation, synthesis of inflammatory markers IL-6, IL-8, and PGE2 and activation of NF-κB and AP-1. Pharmacological inhibition prevented these changes suggesting that AKR1B1 mediates ROS induced inflammation in small airway epithelial cells. Our results indicate that AKR1B1 inhibitors may offer a novel therapeutic approach to treat inflammatory airway diseases such as asthma.",
keywords = "Airway inflammation, Aldose reductase, Asthma, Ragweed pollen extract, ROS",
author = "Yadav, {Umesh C S} and Kota Ramana and Satish Srivastava",
year = "2011",
month = "5",
day = "30",
doi = "10.1016/j.cbi.2011.02.014",
language = "English (US)",
volume = "191",
pages = "339--345",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Aldose reductase inhibition suppresses airway inflammation

AU - Yadav, Umesh C S

AU - Ramana, Kota

AU - Srivastava, Satish

PY - 2011/5/30

Y1 - 2011/5/30

N2 - Airway inflammation induced by reactive oxygen species (ROS)-mediated activation of redox-sensitive transcription factors is the hallmark of asthma, a prevalent chronic respiratory disease. In various cellular and animal models, we have recently demonstrated that, in response to multiple stimuli, aldose reductase (AKR1B1) regulates the inflammatory signals via NF-kappa B activation. Since NF-κB activation is implicated in asthma pathogenesis, we investigated whether AKR1B1 inhibition could prevent ovalbumin (Ova)- and ragweed pollen extract (RWE)-induced airway inflammation and hyper-responsiveness in mice models and tumor necrosis factor-alpha (TNF-α)-, lipopolysachharide (LPS)- and RWE-induced cytotoxic and inflammatory signals in primary human small airway epithelial cells (SAEC). Sensitization and challenge with Ova or RWE caused airway inflammation and production of inflammatory cytokines, accumulation of eosinophils in airways and sub-epithelial regions, mucin production in the bronchoalveolar lavage fluid, airway hyperresponsiveness, elevated IgE levels and release of Th2 cytokines in the airway and treatment with AKR1B1 inhibitors markedly reduced these pathological changes in mice. In SAEC, treatment with TNF-α, LPS or RWE induced apoptosis, reactive oxygen species generation, synthesis of inflammatory markers IL-6, IL-8, and PGE2 and activation of NF-κB and AP-1. Pharmacological inhibition prevented these changes suggesting that AKR1B1 mediates ROS induced inflammation in small airway epithelial cells. Our results indicate that AKR1B1 inhibitors may offer a novel therapeutic approach to treat inflammatory airway diseases such as asthma.

AB - Airway inflammation induced by reactive oxygen species (ROS)-mediated activation of redox-sensitive transcription factors is the hallmark of asthma, a prevalent chronic respiratory disease. In various cellular and animal models, we have recently demonstrated that, in response to multiple stimuli, aldose reductase (AKR1B1) regulates the inflammatory signals via NF-kappa B activation. Since NF-κB activation is implicated in asthma pathogenesis, we investigated whether AKR1B1 inhibition could prevent ovalbumin (Ova)- and ragweed pollen extract (RWE)-induced airway inflammation and hyper-responsiveness in mice models and tumor necrosis factor-alpha (TNF-α)-, lipopolysachharide (LPS)- and RWE-induced cytotoxic and inflammatory signals in primary human small airway epithelial cells (SAEC). Sensitization and challenge with Ova or RWE caused airway inflammation and production of inflammatory cytokines, accumulation of eosinophils in airways and sub-epithelial regions, mucin production in the bronchoalveolar lavage fluid, airway hyperresponsiveness, elevated IgE levels and release of Th2 cytokines in the airway and treatment with AKR1B1 inhibitors markedly reduced these pathological changes in mice. In SAEC, treatment with TNF-α, LPS or RWE induced apoptosis, reactive oxygen species generation, synthesis of inflammatory markers IL-6, IL-8, and PGE2 and activation of NF-κB and AP-1. Pharmacological inhibition prevented these changes suggesting that AKR1B1 mediates ROS induced inflammation in small airway epithelial cells. Our results indicate that AKR1B1 inhibitors may offer a novel therapeutic approach to treat inflammatory airway diseases such as asthma.

KW - Airway inflammation

KW - Aldose reductase

KW - Asthma

KW - Ragweed pollen extract

KW - ROS

UR - http://www.scopus.com/inward/record.url?scp=79957539666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957539666&partnerID=8YFLogxK

U2 - 10.1016/j.cbi.2011.02.014

DO - 10.1016/j.cbi.2011.02.014

M3 - Article

C2 - 21334316

AN - SCOPUS:79957539666

VL - 191

SP - 339

EP - 345

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 1-3

ER -